Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put
MidWestOne Financial Group, Inc. ( MOFG Quick Quote MOFG - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks: PE Ratio
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, MidWestOne has a trailing twelve months PE ratio of 11.04, as you can see in the chart below:
This level actually compares quite favorably with the market at large, as the PE for the S&P 500 stands at about 17.58. Also, if we focus on the long-term PE trend, MidWestOne’s current PE level puts it below its midpoint of 12.64 over the past five years.
Also, the stock’s PE compares favorably with the Finance Market’s trailing twelve months PE ratio, which stands at 14.07. This indicates that the stock is quite undervalued right now, compared to its peers.
Moreover, MidWestOne has a forward PE ratio (price relative to this year’s earnings) of 9.46, which is lower than the current level. So, it is fair to say that a more value-oriented path may be ahead for MidWestOne stock in the near term too.
Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, MidWestOne has a P/S ratio of about 2.23. This is a bit lower than the S&P 500 average, which comes in at 3.15x right now. Also, as we can see in the chart below, this is well below the highs for this stock in particular over the past few years.
Broad Value Outlook
In aggregate, MidWestOne currently has a Value Score of B, putting it into the top 40% of all stocks we cover from this look. This makes MidWestOne a solid choice for value investors.
What About the Stock Overall?
Though MidWestOne might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of D and a Momentum Score of D. This gives MOFG a Zacks VGM score — or its overarching fundamental grade — of C. (You can read more about the Zacks Style Scores
Meanwhile, the company’s recent earnings estimates have been downbeat. The current quarter has seen no upward and two downward revisions in the past sixty days, while the full year estimate has seen one upward revision versus one downward revision in the same time period.
This has had a negative impact on the consensus estimate as the current quarter consensus estimate has dipped 6.4% over the past two months, while the full year estimate has decreased 4.8%. You can see the consensus estimate trend and recent price action for the stock in the chart below:
Despite such bearish analyst sentiments, the stock has a Zacks Rank #3 (Hold) and why we are looking for in-line performance from the company in the near term.
MidWestOne is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. However, with a sluggish industry rank (among Bottom 44% of more than 250 industries) and a Zacks Rank #3, it is hard to get too excited about the stock.
In fact, over the past two years, the broader industry has clearly underperformed the market at large, as you can see below:
So, value investors might want to wait for the rank and industry performance to turn around in this name first, but once that happens, this stock could be a compelling pick.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>